Vertex Pharmaceuticals Forecast, price target & analysts
Vertex Pharmaceuticals Target price 2026 - Analyst rating & recommendation
Vertex Pharmaceuticals Classifications & Recommendation
Vertex Pharmaceuticals Price Target
| Target Price | $589.05 |
| Price | $504.73 |
| Potential | 16.71% |
| Number of Estimates | 30 |
| 30 Analysts have issued a price target Vertex Pharmaceuticals 2027 . The average Vertex Pharmaceuticals target price is $589.05. This is 16.71% higher than the current stock price. The highest price target is $705.60 39.80% , the lowest is $353.50 29.96% . | |
| A rating was issued by 36 analysts: 29 Analysts recommend Vertex Pharmaceuticals to buy, 6 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Vertex Pharmaceuticals stock has an average upside potential 2027 of 16.71% . Most analysts recommend the Vertex Pharmaceuticals stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
34 Analysts have issued a sales forecast Vertex Pharmaceuticals 2026 . The average Vertex Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Vertex Pharmaceuticals EBITDA forecast 2026. The average Vertex Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
35 Vertex Pharmaceuticals Analysts have issued a net profit forecast 2026. The average Vertex Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
35 Analysts have issued a Vertex Pharmaceuticals forecast for earnings per share. The average Vertex Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Vertex Pharmaceuticals...
Current Vertex Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Buy
➜
Buy
|
Unchanged | Sep 28 2026 |
| JP Morgan |
➜
Overweight
|
Unchanged | Sep 11 2026 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Sep 02 2026 |
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Aug 05 2026 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Aug 05 2026 |
| Canaccord Genuity |
Hold
➜
Hold
|
Unchanged | Aug 04 2026 |
| Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Aug 04 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
UBS:
Buy
➜
Buy
|
Sep 28 2026 |
|
Unchanged
JP Morgan:
➜
Overweight
|
Sep 11 2026 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Sep 02 2026 |
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Aug 05 2026 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Aug 05 2026 |
|
Unchanged
Canaccord Genuity:
Hold
➜
Hold
|
Aug 04 2026 |
|
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Aug 04 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
